TRCT
PCSA icon

Tower Research Capital (TRC)’s Processa Pharmaceuticals PCSA Stock Holding History

Tower Research Capital (TRC)’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.8K Buy
2,499
+1,581
+172% +$4.09K ﹤0.01% 4343
2026
Q1 		$2.32K Sell
918
-472
-34% -$1.29K ﹤0.01% 4498
2025
Q4 		$4K Buy
1,390
+1,294
+1,348% +$9.04K ﹤0.01% 4275
2025
Q3 		$459 Sell
96
-2
-2% -$11 ﹤0.01% 5009
2025
Q2 		$505 Sell
98
-1
-1% -$7 ﹤0.01% 5005
2025
Q1 		$913 Buy
99
+1
+1% +$15 ﹤0.01% 4803
2024
Q4 		$2.18K Sell
98
-48
-33% -$1.35K ﹤0.01% 4890
2024
Q3 		$4.99K Buy
146
+26
+22% +$1.02K ﹤0.01% 4351
2024
Q2 		$6.72K Sell
120
-60
-33% -$2.95K ﹤0.01% 4550
2024
Q1 		$10.7K Buy
180
+178
+8,900% +$14.1K ﹤0.01% 3671
2023
Q4 		$400 Sell
2
-18
-90% -$4.02K ﹤0.01% 5585
2023
Q3 		$2.52K Buy
20
+2
+11% +$378 ﹤0.01% 5138
2023
Q2 		$4.38K Hold
18
– – ﹤0.01% 4955
2023
Q1 		$4K Buy
18
+2
+13% +$806 ﹤0.01% 5098
2022
Q4 		$9K Buy
16
+7
+78% +$6.76K ﹤0.01% 4238
2022
Q3 		$10K Buy
9
+6
+200% +$8.82K ﹤0.01% 4562
2022
Q2 		$4K Sell
3
-3
-50% -$4.11K ﹤0.01% 5242
2022
Q1 		$9K Buy
6
+3
+100% +$5.71K ﹤0.01% 4474
2021
Q4 		$8K Buy
+3
New +$9.3K ﹤0.01% 4814
2021
Q2 		– Hold
0
– -$3K – 5745
2021
Q1 		– Sell
-3
Closed -$14K – 4914
2020
Q4 		$9K Buy
+3
New +$8.33K ﹤0.01% 4394

Other funds holding PCSA

CCM
Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Tower Research Capital (TRC)'s PCSA Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Processa Pharmaceuticals (PCSA) stake by 172% in Q2 2026, buying an estimated $4.09K and bringing the position to 2,499 shares worth $4.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4343.

Tower Research Capital (TRC) first reported a position in PCSA in Q4 2020 and has held it in 20 quarters since. The position peaked at $10.7K in Q1 2024. 11 funds tracked by Wall St. Rank hold PCSA as of Q2 2026.

  • Tower Research Capital (TRC) held 2,499 shares of Processa Pharmaceuticals worth $4.8K as of Q2 2026.
  • Tower Research Capital (TRC) bought 1,581 Processa Pharmaceuticals shares in Q2 2026, an estimated $4.09K.
  • Processa Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4343 holding.
  • Tower Research Capital (TRC) first reported a position in Processa Pharmaceuticals in Q4 2020 and has held it in 20 quarters since.
  • Tower Research Capital (TRC)'s Processa Pharmaceuticals position peaked at $10.7K in Q1 2024.
  • 11 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.